Manufacturing news briefs — stories you might have missed

Cyclopharm raises $20 million, seeks another $2 million Radiopharmaceutical imaging company Cyclopharm has successfully completed its institutional placement, raising $20 million before costs. The Placement attracted strong demand from both existing shareholders and from new institutional and sophisticated investors in Australia, Hong Kong, and the UK. A share purchase plan to raise up to $2.0…

Cyclopharm achieves streamlined reimbursement for Technegas in the US

Cyclopharm’s Technegas radiopharmaceutical imaging system has achieved a streamlined reimbursement approval process in the United States, boosting its prospects in what is the world’s largest market. The Sydney company has received a Coding Determination for Technegas from the Center for Medicare Medicaid Services (CMS), which means users will have a unique identifier which streamlines their…

Manufacturing news briefs — stories you might have missed

Viraleze shows efficacy in Covid-19 patients – Starpharma Starpharma’s Viraleze antiviral nasal spray has demonstrated antiviral efficacy in a placebo-controlled study in participants with Covid-19. Viraleze achieved a statistically significant reduction in SARS-CoV-2 viral load, in the cohort of participants aged 45 and over. Viral load in the nose was reduced by 80 percent less…

Cyclopharm’s Technegas approved for US market in sales milestone

The US Food and Drug Administration has approved Cyclopharm’s lung imagining technology Technegas, opening up a US$180 million market that has the potential to quadruple the size of Cyclopharm’s existing Pulmonary Embolism (PE) market. Technegas is an ultra-fine dispersion of the radiopharmaceutical Technetium-99m within a gas used in diagnostic functional lung imaging in 64 countries…